Diagnostics firm finalizes Matritech acquisition

Inverness Medical Innovations, Inc. has finalized its acquisition of Matritech, Inc., the manufacturer of the NMP22 BladderChek Test.

The BladderChek is a point-of-care test cleared by the FDA for both the diagnosis and monitoring of bladder cancer. Inverness is an international developer of point-of-care diagnostics related to infectious disease, cardiology, oncology, drugs of abuse, and women’s health.

“Matritech’s expertise in the development of protein-based diagnostic products for the early detection of cancer is a terrific addition to the Inverness portfolio of products and capabilities, said Ron Zwanziger, CEO of Inverness.